Bleichroeder LP 13D and 13G filings for Evoke Pharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-03-24 6:47 pm Sale | 2025-03-24 | 13G | Evoke Pharma, Inc. EVOK | Bleichroeder LP | 158,058 9.990% | -691,309 (-81.39%) | Filing |
| 2025-03-21 7:15 pm Purchase | 2025-03-19 | 13G | Evoke Pharma, Inc. EVOK | Bleichroeder LP | 849,367 9.990% | 778,586 (+1100.00%) | Filing |
| 2024-03-11 6:39 pm Purchase | 2024-02-13 | 13G | Evoke Pharma, Inc. EVOK | Bleichroeder LP | 70,781 9.990% | 70,781 (New Position) | Filing |